IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous Placebo
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anaemia
Conditions
Anaemia
Trial Timeline
May 1, 2007 → May 1, 2009
NCT ID
NCT01078818About IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous Placebo
IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous Placebo is a approved stage product being developed by Rafael Holdings for Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01078818. Target conditions include Anaemia.
What happened to similar drugs?
1 of 4 similar drugs in Anaemia were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01078818 | Approved | Completed |
Competing Products
11 competing products in Anaemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-1093 + placebo | Daiichi Sankyo | Phase 1 | 29 |
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Neorecormon | Roche | Approved | 43 |
| SAR445088 | Sanofi | Phase 1 | 21 |
| BIVV020 | Sanofi | Phase 1 | 29 |
| G-CSF + Early retreatment with ATG | Sanofi | Phase 3 | 32 |
| rilzabrutinib + placebo | Sanofi | Phase 3 | 47 |
| Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland) | Sandoz Group | Phase 3 | 37 |
| Ferric Maltol | Medpace | Phase 1 | 26 |